Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoniazid + levofloxacin + ethambutol
- Development stage
- Unknown
- Lead developer
- Institute of Liver and Biliary Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
9HLE is a 9-month anti-tubercular treatment regimen comprising isoniazid, levofloxacin, and ethambutol. Developed by the Institute of Liver and Biliary Sciences in India, it is specifically intended for treating tuberculosis in patients with underlying compensated or decompensated chronic liver disease. By replacing potentially hepatotoxic agents like rifampicin and pyrazinamide with levofloxacin, the regimen aims to provide an effective therapeutic option while minimizing the risk of drug-induced liver injury. Isoniazid acts by inhibiting mycolic acid synthesis, levofloxacin targets bacterial DNA gyrase and topoisomerase IV, and ethambutol interferes with cell wall assembly by inhibiting arabinosyl transferase.
- Other names
- 9HLE regimenHLE regimenModified anti-tubercular regimen
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)embA (Arabinosyltransferase A)InhA
Beyond the preview
Go deeper on isoniazid + levofloxacin + ethambutol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isoniazid + levofloxacin + ethambutol.